(Sharecast News) - hVivo reported positive topline results from a phase 2b field study conducted on behalf of Cidara Therapeutics on Monday, for which it provided participant recruitment, virology, and immunology laboratory services.
The AIM-traded firm said the study evaluated CD388, a drug-Fc conjugate designed as a non-vaccine preventative for seasonal...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE